BACKGROUND: Guidelines recommend against treating localized prostate cancer (PCa) in men with a greater than 10-year life expectancy. However, physicians have difficulty accurately estimating life expectancy. OBJECTIVE: We used data from a population-based observational study to develop a nomogram to estimate long-term other-cause mortality based on self-reported health status (SRHS), race/ethnicity, and age at diagnosis. DESIGN: This was an observational study. SUBJECTS: Men diagnosed with localized PCa from October 1994 through October 1995 participated in the study. MAIN MEASURES: Initial measures obtained 6 months after diagnosis included sociodemographic and tumor characteristics, treatment, and a single item on the SRHS, with response options ranging from excellent to poor. We used Surveillance, Epidemiology, and End-Results program data to determine date and cause of death through December 2010. We estimated other-cause mortality with proportional hazards survival analyses, accounting for competing risks. KEY RESULTS: We evaluated 2,695 men, of whom 74% underwent aggressive therapy (surgery or radiotherapy). At the initial survey, 18% reported excellent (E), 36% very good (VG), 31% good (G), and 15% fair/poor (F/P) health. Healthier men were younger, and more likely to be white, better educated, and to undergo surgery. At follow-up, 44% of the cohort had died; 78% of deaths were from causes other than PCa. SRHS predicted other-cause mortality; for men reporting E, VG, G, F/P health, the cumulative incidences of other-cause mortality were 20%, 29%, 40%, and 53%, respectively, p < 0.001. Compared to a reference of excellent SRHS, multivariable hazard ratios (95% CI) for other-cause mortality for men reporting VG, G, and F/P health were 1.22 (0.97-1.54), 1.73 (1.38-2.17), and 2.71 (2.11-3.48), respectively. CONCLUSIONS: Responses to a one-item SRHS measure were strongly associated with other-cause mortality 15 years after PCa diagnosis. Men reporting fair/poor health had substantial risks for other-cause mortality, suggesting limited benefit for undergoing aggressive treatment. SRHS can be considered in supporting informed decision-making about PCa treatment.
BACKGROUND: Guidelines recommend against treating localized prostate cancer (PCa) in men with a greater than 10-year life expectancy. However, physicians have difficulty accurately estimating life expectancy. OBJECTIVE: We used data from a population-based observational study to develop a nomogram to estimate long-term other-cause mortality based on self-reported health status (SRHS), race/ethnicity, and age at diagnosis. DESIGN: This was an observational study. SUBJECTS:Men diagnosed with localized PCa from October 1994 through October 1995 participated in the study. MAIN MEASURES: Initial measures obtained 6 months after diagnosis included sociodemographic and tumor characteristics, treatment, and a single item on the SRHS, with response options ranging from excellent to poor. We used Surveillance, Epidemiology, and End-Results program data to determine date and cause of death through December 2010. We estimated other-cause mortality with proportional hazards survival analyses, accounting for competing risks. KEY RESULTS: We evaluated 2,695 men, of whom 74% underwent aggressive therapy (surgery or radiotherapy). At the initial survey, 18% reported excellent (E), 36% very good (VG), 31% good (G), and 15% fair/poor (F/P) health. Healthier men were younger, and more likely to be white, better educated, and to undergo surgery. At follow-up, 44% of the cohort had died; 78% of deaths were from causes other than PCa. SRHS predicted other-cause mortality; for men reporting E, VG, G, F/P health, the cumulative incidences of other-cause mortality were 20%, 29%, 40%, and 53%, respectively, p < 0.001. Compared to a reference of excellent SRHS, multivariable hazard ratios (95% CI) for other-cause mortality for men reporting VG, G, and F/P health were 1.22 (0.97-1.54), 1.73 (1.38-2.17), and 2.71 (2.11-3.48), respectively. CONCLUSIONS: Responses to a one-item SRHS measure were strongly associated with other-cause mortality 15 years after PCa diagnosis. Men reporting fair/poor health had substantial risks for other-cause mortality, suggesting limited benefit for undergoing aggressive treatment. SRHS can be considered in supporting informed decision-making about PCa treatment.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson Journal: J Comp Eff Res Date: 2013-07 Impact factor: 1.744
Authors: Jochen Walz; Andrea Gallina; Paul Perrotte; Claudio Jeldres; Quoc-Dien Trinh; Georg C Hutterer; Miriam Traumann; Alvaro Ramirez; Shahrokh F Shariat; Michael McCormack; Jean-Paul Perreault; Francois Bénard; Luc Valiquette; Fred Saad; Pierre I Karakiewicz Journal: BJU Int Date: 2007-12 Impact factor: 5.588
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Nadia A Nabulsi; Ali Alobaidi; Brian Talon; Alemseged A Asfaw; Jifang Zhou; Lisa K Sharp; Karen Sweiss; Pritesh R Patel; Naomi Y Ko; Brian C-H Chiu; Gregory S Calip Journal: Cancer Causes Control Date: 2020-04-30 Impact factor: 2.506
Authors: Gregory T Chesnut; Amy L Tin; Katherine A Fleshner; Nicole E Benfante; Andrew J Vickers; James A Eastham; Daniel D Sjoberg; Sigrid V Carlsson Journal: Prostate Cancer Prostatic Dis Date: 2021-11-03 Impact factor: 5.554
Authors: Stephen McMahon; Ram Basak; Xi Zhou; Angela B Smith; Lixin Song; Raj S Pruthi; Eric M Wallen; Matthew E Nielsen; Hung-Jui Tan Journal: Urology Date: 2020-12-19 Impact factor: 2.649
Authors: Margaret Peggy Adamo; Jessica A Boten; Linda M Coyle; Kathleen A Cronin; Clara J K Lam; Serban Negoita; Lynne Penberthy; Jennifer L Stevens; Kevin C Ward Journal: Cancer Date: 2016-10-26 Impact factor: 6.860
Authors: Daniel M Frendl; Gordon FitzGerald; Mara M Epstein; Jeroan J Allison; Mitchell H Sokoloff; John E Ware Journal: PLoS One Date: 2020-12-07 Impact factor: 3.240
Authors: Smith Giri; Nabiel Mir; Mustafa Al-Obaidi; Deanna Clark; Kelly M Kenzik; Andrew McDonald; Crystal Young-Smith; Ravi Paluri; Lakshmin Nandagopal; Olumide Gbolahan; Kirsten A Nyrop; Hyman B Muss; Mackenzi Pergolotti; Smita Bhatia; Grant R Williams Journal: Oncologist Date: 2022-02-03 Impact factor: 5.837
Authors: Elizabeth C Chase; Alex K Bryant; Yilun Sun; William C Jackson; Daniel E Spratt; Robert T Dess; Matthew J Schipper Journal: BJU Int Date: 2022-04-24 Impact factor: 5.969
Authors: Hyunsoon Cho; Zhuoqiao Wang; K Robin Yabroff; Benmei Liu; Timothy McNeel; Eric J Feuer; Angela B Mariotto Journal: BMC Public Health Date: 2022-01-20 Impact factor: 3.295